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Summary
Objective: To investigate the mechanism of aggrecanolysis in interleukin-1 (IL-1)-treated cartilage tissue by examining the time course of
aggrecan cleavages and the tissue and medium content of membrane type 4-matrix metalloproteinases (MT4-MMP) and a disintegrin and
metalloproteinase with thrombospondin type I motifs (ADAMTS)4.
Methods: Articular cartilage explants were harvested from newborn bovine femoropatellar groove. The effects of IL-1 treatment with or without
aggrecanase blockade were investigated by Western analysis of aggrecan fragment generation, ADAMTS4 species (p68 and p53), and MT4-
MMP, as well as by realtime PCR (polymerase chain reaction) for ADAMTS4 and 5. Aggrecanase was blocked with mannosamine (ManN), an
inhibitor of glycosylphosphatidylinositol anchor synthesis, and esculetin (EST), an inhibitor of MMP-1, MMP-3, and MMP-13 gene expression.
Results: IL-1 treatment caused a major increase in MT4-MMP abundance in the tissue and medium. ADAMTS4 (p68) was abundant in fresh
cartilage and this was retained in the tissue in untreated cartilage. IL-1 treatment for 6 days caused a marked loss of p68 from the cartilage and
the appearance of p53 in the medium. Addition of either 1.35 mM ManN or 31e500 mM EST blocked IL-1-mediated aggrecanolysis and this
was accompanied by nearly complete inhibition of the MT4-MMP increase, the p68 loss and the formation of p53. IL-1 treatment increased
mRNA abundance for ADAMTS4 (w3-fold) and ADAMTS5 (w10-fold) but this was not accompanied by a marked change in enzyme protein
abundance.
Conclusion: These studies support a central role for MT4-MMP in IL-1-induced cartilage aggrecanolysis and are consistent with the
identiﬁcation of p68 as the aggrecanase that cleaves within the CS2 domain, and of p53 as the aggrecanase that generates G1-NITEGE.
Since the induction by IL-1 was not accompanied by marked changes in total ADAMTS4 protein, but rather in partial conversion of p68 to p53
and release of both from the tissue, we conclude that aggrecanolysis in this model system results from MT4-MMP-mediated processing of
a resident pool of ADAMTS4 and release of the p68 and p53 from their normal association with the cell surface.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Enhanced release of proteoglycans from the articular
cartilage to the synovial ﬂuid is a prominent feature of early
and late osteoarthritis. In particular, aggrecan is the most
abundant proteoglycan in cartilage tissue and provides
much of the tissue’s compressive strength through electro-
static repulsion of its tightly packed glycosaminoglycan
(GAG) chains1. Excess degradation of aggrecan in the
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Received 2 June 2004; revision accepted 25 October 2004.26cartilage tissue thus contributes directly to the failure of the
mechanical function of the joint.
Investigation of enzymatic degradation of aggrecan has
led to the identiﬁcation of speciﬁc cleavage sites generated
by enzymes termed aggrecanases, which have since been
identiﬁed as a sub-group (ADAMTS1,4,5,8,9,15)2-4 of the 19-
member family of ADAMTS (a disintegrin and metalloprotei-
nase with thrombospondin type I motifs) proteinases5,6. It is
now clear that degradation of aggrecan induced by major
inﬂammatory cytokines such as interleukin-1 (IL-1) and
tumor necrosis factor is mediated by the action of the
aggrecanases and not the matrix metalloproteinases
(MMPs)7e10. In addition, the evidence for aggrecanase-
mediated cleavage of aggrecan in cartilage tissue and
synovial ﬂuid from patients with osteoarthritis11,12 suggests
that aggrecanase activity is predominantly or maybe
exclusively responsible for the excess degradation of
cartilage aggrecanwhich is a feature of human osteoarthritis.
Recently, the steps involved in processing of ADAMTS4
(aggrecanase-1) have been described in a human chon-
drosarcoma cell line stably transfected with ADAMTS4, and9
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terized. To exhibit any aggrecanase activity, the ADAMTS4
proenzyme ﬁrst requires intracellular furin-mediated re-
moval of the N-terminal pro-domain13, which generates
the p68 form. While this form can degrade the C-terminal
chondroitin sulfate (CS)-bearing region, it appears that for
‘‘destructive’’ cleavage of aggrecan in the interglobular
domain (IGD), further C-terminal truncation of ADAMTS4 is
required2,14,15, producing the p53 and p40 forms of the
proteinase. We have previously hypothesized that this C-
terminal truncation requires a glycosylphosphatidylinositol
(GPI)-linked MMP, since IGD cleavage is blocked by
inhibitors of GPI anchor synthesis such as mannosamine
(ManN) and by MMP inhibitors2,16. This was recently
supported by the ﬁnding that transfection of ADAMTS4-
expressing cells with membrane type 4-MMP (MT4-MMP)
(a GPI-anchored MMP17) promoted C-terminal processing
of ADAMTS4 to the p53 and p40 forms and acquisition of
IGD cleavage activity18.
However, there has been no detailed description of the
processing of ADAMTS4 in native cartilage tissue. Initial
studies of the protein forms present in normal and IL-1-
stimulated cartilage have shown evidence for ADAMTS4
forms in the ranges 30e60 kDa9 and 37e46 kDa14, and the
effect of IL-1 treatment on levels of MT4-MMP protein in
cartilage has not been reported.
We therefore examined aggrecan degradation in new-
born bovine cartilage explants treated with IL-1 by Western
analysis of aggrecan, ADAMTS4 and MT4-MMP in the
cartilage tissue and conditioned medium. In addition, we
examined the effects of two aggrecanase blockers,
ManN16,19,20 and esculetin (EST)21. We hypothesized that
as an inhibitor of GPI anchor synthesis16,20,22, ManN would
interfere with the processing of the p68 form to the p53
form. The mechanism for aggrecanase inhibition by EST is
not clear but it appears to inhibit MMP gene expression21,23,
and thus allows investigation of the effects of aggrecanase
blockade through what is likely a different mechanism than
ManN. Finally, to investigate regulation of aggrecanase
activity at the level of transcription, we measured the effect
of IL-1 and ManN treatment on mRNA expression of
ADAMTS4 and ADAMTS5 by realtime PCR analysis.
Methods
MATERIALS
Human recombinant IL-1a was from R&D Systems, Inc.,
Minneapolis, MN. Unless indicated, other reagents were
from Sigma Chemical Co. (St. Louis, MO).
CARTILAGE EXPLANT AND CULTURE
Articular cartilage disks were obtained from the femo-
ropatellar groove of one-to-two-week-old calves, a model
system that has been widely studied to examine the
biological response pathways relevant to cartilage degra-
dation in human osteoarthritis24, using methods similar to
those described in detail previously25. In brief, 9-mm-
diameter cylinders of full-thickness cartilage and bone were
cored from the articular cartilage. After slicing off sufﬁcient
superﬁcial cartilage to create a ﬂat surface (usually less
than 500 mm), the next two sequential 0.5-mm-thick slices
were cut with a sledge microtome. From each of these
slices, four cartilage disks (3 mm in diameter and 0.5 mm in
thickness) were cut out with a dermal punch. Groups ofcartilage disks were incubated at 37(C in an atmosphere of
5% CO2, in wells containing 0.25 ml/disk of a serum-free
culture medium (low-glucose DMEM [Dulbecco’s modiﬁed
Eagle’s medium] [Gibco, Grand Island, NY] and 10 mM
HEPES buffer, with 100 U/ml penicillin G, 100 mg/ml
streptomycin and 0.25 mg/ml amphotericin B). Experimental
treatments with IL-1 and aggrecanase blockers were begun
on the day of harvest. With the exception of the kinetic
analysis, these cultures were incubated without medium
replacement for up to 6 days. Each experiment had four to
eight treatment groups, allowing disks among different
groups to be matched for their original location along the
surface of the joint.
BIOCHEMICAL ANALYSIS OF PROTEOGLYCANS
Tissue and medium were analyzed for composition of
aggrecan fragments by Western blotting as previously
described26. Aggrecan remaining in the cartilage tissue
was extracted in 4 Mguanidine (1.2 ml per 75 mgwet weight)
for 48 h at 4(C in the presence of proteinase inhibitors.
Aggrecan fragments in tissue extracts and conditioned
medium were isolated by ethanol precipitation and deglyco-
sylated. Portions of medium and tissue extracts (correspond-
ing to 10 mg GAG in each case) were loaded on 4e12%
polyacrylamide gels (Novex) for Western analysis and
probed with polyclonal antisera to the bovine G1 domain
(G1-2), the G3 domain (antibody LEC-7, provided by Dr Kurt
Doege) and the C-terminal neoepitopes TFKEEE1706 (anti-
serumprovided byMerck), TAGELE1520 (antiserum provided
by DuPont), and NITEGE392 (antibody JSCNIT). Tissue
(digested overnight with proteinase K) and conditioned
medium were assayed for sulfated GAG content by reaction
with dimethylmethylene blue (DMMB) dye.
WESTERN ANALYSIS OF ADAMTS4 (AGGRECANASE-1)
AND MT4-MMP
Pilot studies were done to optimize the extraction
conditions for ADAMTS4 in cartilage. Cartilage (15 mg wet
weight) was freeze-milled in a Biopulverizer (Biospec
Products, Bartlesville, OK) and the powder was extracted
for 20 h at 4(C in three volumes (ml/mg wet weight) of (1)
50 mMTriseHCl, pH7.0; (2) 50 mMTriseHCl, 100 mMNaCl,
pH 7.0; (3) 50 mM TriseHCl, 100 mMNaCl, 0.5%Nonidet P-
40, pH 7.0; or (4) 4 M guanidine, 50 mM TriseHCl, pH 7.0.
Macromolecules in the 4 Mguanidine extractwere puriﬁed by
Sephadex G50 and DE 52 as previously described for
aggrecan fragments27 and the unbound (protein) and bound
(proteoglycan) fractions were analyzed. Other cartilage
sampleswere treatedat 100(C for 10 min in 50 mMTriseHCl
and 2.5% SDS. The results of the comparative extraction
experiments (not shown) indicated that the highest yield of
immunoreactive product was consistently obtained with
extractant (3). Poor recoveries were seen with 4 M guanidine
extracts and boiling in SDS. Therefore, all data shown in the
present paper were obtained using extraction with 0.5%
Nonidet P-40, 50 mM Tris, and 100 mM NaCl at pH 7.0, and
dilution of 5e10 ml of the extracts in gel-loading buffer before
SDS-PAGE (sodium dodecyl sulfateepolyacrylamide gel
electrophoresis). Conditioned medium from cartilage ex-
plantswasconcentrated by lyophilization, dialyzed, driedand
dissolved in gel-loading buffer.
Western analysis of ADAMTS4 was done with two
afﬁnity-puriﬁed antibodies that exhibit different reactivities
for the molecular forms of ADAMTS42. JSCVMA was raised
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preferentially reacts with the p53 form in tissue extracts.
JSCYNH was raised to a peptide (Tyr590ePro603) within the
Cys-rich region and it reacts preferentially with the p68
form. All soluble samples were loaded on an equivalent
tissue weight basis and separate blots were probed with
JSCYNH or JSCVMA. For Western analysis of MT4-MMP
(MMP-17), blots were probed with antibodies to MT4-MMP
from Sigma (catalog #M3684).
REALTIME PCR ANALYSIS
RNA was extracted from cartilage disks after 24 h of
treatment and analyzed by realtime PCR. Frozen cartilage
was pulverized and then homogenized in Trizol reagent
(Invitrogen, Carlsbad, CA). After addition of 10% v/v
chloroform, the samples were centrifuged at 13,000 g for
10 min in phase-lock gel tubes (Eppendorf AG, Hamburg,
Germany). The aqueous supernatant was collected, and
RNA was isolated with the RNeasy Mini Kit (Qiagen,
Valencia, CA). Extracted RNA concentration and purity was
measured by optical density at 260 and 280 nm. Equal
quantities of RNA from each sample were reverse
transcribed with the Amplitaq Gold RT kit (Applied
Biosystems, Foster City, CA). Realtime PCR was per-
formed with the Applied Biosystems 7700 instrument and
SYBR Green Master Mix (Applied Biosystems). Primers
were designed as described previously28.
For statistical analysis of mRNA expression levels, mRNA
copy number was ﬁrst log-transformed to normalize the
distribution of the data. Since the experiment was designed
as a factorial experiment, linear regression was performed to
test for the effects of the two factors (ManN and IL-1) as well
as for an interaction between the effects of ManN and IL-1.
Two indicator variables were also included to adjust for
proportional changes in baseline between experiments.
Results
KINETICS OF AGGRECAN DEGRADATION IN CALF EXPLANTS
TREATED WITH IL-1
In preliminary experiments to describe the kinetics of
IL-1-induced aggrecan degradation in the newborn bovine
cartilage tissue, we obtained cartilage disks with a deﬁned
cylindrical geometry and treated them with 1, 10 and
100 ng/ml IL-1a. At 2, 4, and 6 days the cultures were
terminated and the proportion of total GAG remaining in the
tissue as well as the equilibrium and dynamic compressive
moduli were measured. This analysis (data not shown)
revealed that for explants cut to 0.5 mm in thickness, the
addition of IL-1 at 10 ng/ml generated a gradual catabolic
response which was most appropriate for kinetic analysis
over 6 days.
We therefore treated cartilage explants with 10 ng/ml for
6 days and terminated cultures at eight different times (0,
0.5, 1, 1.5, 2, 2.5, 3, 4.5, and 6 days), with removal of
medium and replacement with fresh medium and IL-1 at
days 2 and 4.5. To examine the composition of aggrecan
remaining in the tissue at these times, we performed
a Western analysis with anti-aggrecan G1 domain on the
tissue extracts [Fig. 1(A)]. The composition of the control
tissue (maintained in culture without IL-1 for 6 days) and
fresh tissue (maintained for 0 days) was primarily core
species 1 (full-length aggrecan) with a low abundance of
species a, b, c and d, which are not generated byaggrecanase action (see Fig. 2 for peptide notations). Early
in the IL-1 treatment period (days 1 and 1.5), species a and
b appeared to be eliminated from the tissue, whereas from
days 2e6 there was an accumulation in the tissue of
species 5 (G1-TAGELE) at about 250 kDa. Western
analysis of these samples with anti-TAGELE and anti-
TFKEEE conﬁrmed that the abundance of these aggreca-
nase-generated species (at about 200e250 kDa) was
increased during days 2e6, in parallel with the appearance
of the G1-reactive band(s) in that region of the gel (data not
shown). Interestingly, the N-terminal product G1-NITEGE
(species 6 doublet) was not observed until day 4.5 of
culture, consistent with the common ﬁnding that IL-1-
promoted aggrecanase-mediated aggrecan degradation
occurs in a stepwise fashion, with the C-terminal region
being degraded before cleavage of the IGD9,16,29.
This interpretation was supported by Western analysis of
the medium collected over various periods during this
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Fig. 1. Kinetics of aggrecanolysis by IL-1 treatment in 0.5-mm-thick
newborn bovine articular cartilage explants. Cartilage cultures
treated with 10 ng/ml were terminated at various times during a
6-day experiment. (A) Aggrecan remaining in the tissue was
extracted and Western analysis performed with an antibody to
aggrecan G1 domain (G1-2). (B) Western analysis of aggrecan
fragments released to the corresponding conditioned medium was
performed with an antibody to aggrecan G3 domain (LEC-7).
Portions of tissue and medium were loaded on an equal-GAG
basis. See Fig. 2 for peptide identiﬁcations.
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‘‘ladder’’ of G3-reactive species labeled as 7, 8, 9, and 10
are characteristic of aggrecanase-mediated C-terminal
processing during the early period (days 0e3), whereas
the relative paucity of these products in medium collected
after day 4.5 is consistent with aggrecanase cleavage now
being targeted to the IGD. This was veriﬁed by Western
analysis of the medium for the G1 domain, which showed
nearly undetectable G1-NITEGE release until day 4.5, and
no evidence for higher-molecular-weight G1-bearing frag-
ments (data not shown), as observed in this system
previously30. An unidentiﬁed G3-reactive fragment at about
44 kDa was a major medium product at all time periods, and
this migration behavior is consistent with the isolated
globular region of the G3 domain of bovine aggrecan. The
proteinase responsible for the generation of this species is
unknown; however, the same or similar product is readily
generated from bovine aggrecan by m-calpain digestion31.
Analysis of the tissue extracts with the anti-G3 antibody
detected only the full-length core protein (data not shown),
suggesting that these G3-bearing fragments diffuse rapidly
into the medium once formed.
ANALYSIS OF EXPLANT SYSTEM FOR ADAMTS4 PROTEIN
Since it was clear that an active aggrecanase was
present in this system, and since it has been suggested that
ADAMTS4 (rather than TS-1, 5, 8, 9 or 15) is mostly
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Fig. 2. Schematic of the structures for bovine aggrecan core protein
peptides. The diagram shows the currently accepted structures for
aggrecan core protein peptides derived from bovine cartilage
explants before and after treatment with IL-1 (see Fig. 1). The
sequences and residue numbers shown are taken from data in
Hering et al.50 for bovine aggrecan (accession number AAB38524),
and the identiﬁcations are taken from Oshita et al.31 and references
therein. Note that these residue numbers differ from previous
reports11,29 by a constant offset of 19 to conform with genome-
based numbering of the leader sequence. Peptides identiﬁed with
the numbers 5e10 represent aggrecanase-generated aggrecan
species.responsible for this activity4,9,32-35, we analyzed both tissue
and medium for ADAMTS4 in control cultures, IL-1-treated
cultures, and IL-1-treated cultures with the addition of
1.35 mM ManN. Consistent with our previous ﬁndings29, in
this experiment GAG released from the cartilage to the
medium increased from 24G 2 mg/disk in controls to
115G 6 mg/disk in IL-1-treated cultures, and this aggreca-
nase-mediated degradation was blocked by the addition of
ManN (40G 3 mg/disk; all NZ 4 disks per group).
Extracts of untreated control tissue at days 0 and 6,
probed with JSCYNH (Fig. 3, tissue), contained a single
major immunoreactive protein which was identiﬁed as the
p68 form. Since this antibody reacts with the proenzyme in
cell culture experiments, the absence of immunoreactive
proenzyme here suggests that either the proenzyme does
not accumulate in the tissue or it is poorly reactive in these
extracts, perhaps due to the presence of masking proteins.
After 6 days of IL-1 treatment, the p68 form was essentially
eliminated from the tissue, a process which was markedly
blocked by the inclusion of ManN. Analysis of the medium
showed that under control conditions, some of the p53 form
(and an unidentiﬁed fragment of about 30 kDa) was
released from the tissue, unlike the p68 form, which
remained associated with the tissue. In marked contrast,
abundant p68 and p53 were released into the medium after
treatment with IL-1 for 6 days; however, the inclusion of
ManN returned this process to control levels.
ANALYSIS OF EXPLANT SYSTEM FOR MT4-MMP PROTEIN
To examine the possibility that GPI-anchored MT4-MMP
is involved in processing of ADAMTS4 in bovine cartilage,
the tissue and conditioned medium from this experiment
were further examined by Western analysis for MT4-MMP
(MMP-17) protein (Fig. 4). In fresh tissue (day 0), a trace
amount of MT4-MMP protein was detected, whereas in
control tissue and medium at 6 days it was not detectable.
In contrast, analysis of tissue treated with IL-1 showed
a marked increase in MT4-MMP abundance atw65 kDa (a
size consistent with previous observations in cells and
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Fig. 3. Western analysis of ADAMTS4 in cartilage tissue and
conditioned medium with JSCYNH. Cartilage was analyzed
immediately after harvest (Day 0) or incubated for 6 days in
serum-free medium with no treatment, 10 ng/ml IL-1, or IL-1 plus
1.35 mM ManN. Conditioned medium was concentrated and
loaded on an equal volume basis (500 ml). IL-1 treatment resulted
in a loss of tissue p68 to the medium and an increase in abundance
of the p53 in the medium that was blocked by addition of ManN.
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largely reversed on addition of ManN. Similarly, analysis
of the collected conditioned medium showed an increased
abundance of MT4-MMP protein in IL-1-treated cultures that
was blocked by inclusion of ManN. The nature of the minor
immunoreactive product at w80 kDa is unknown.
EFFECT OF EST ON IL-1-INDUCED CHANGES
EST (dihydroxycoumarin) has previously been shown to
inhibit cartilage degradation induced by the combination of
IL-1 and oncostatin M, but the mechanism is not
clear21,23,37. We therefore performed a parallel set of
experiments, ﬁrst demonstrating inhibition of IL-1-induced
aggrecanase activity by EST, and then testing whether EST
also reversed IL-1-induced changes in ADAMTS4 and
MT4-MMP protein. Cartilage explants were incubated in the
presence or absence of 10 ng/ml IL-1 and EST for 6 days,
with doses from 31 mM to 500 mM EST. EST was solubilized
in dimethylsulfoxide (DMSO) at a concentration sufﬁcient to
ensure that the ﬁnal concentration of DMSO did not exceed
0.5% in any culture medium.
EST inhibited GAG loss from tissue in a dose-dependent
manner [Fig. 5(A)], and had marked effects on both the
abundance and distribution of ADAMTS4 [Fig. 5(B)] and
MT4-MMP [Fig. 5(C)]. In this experiment, the control
cartilage contained the p68 form of ADAMTS4, and no
detectable ADAMTS4 was released during culture for
6 days. In the presence of IL-1, there was a loss of p68
from the tissue and appearance of p53 in the medium.
While the Western analysis suggests an increase in total
immunoreactive ADAMTS4, this may be misleading since
the antibody used (JSCVMA) reacts preferentially
with the p53 form (see Methods). EST markedly blocked
this IL-1-mediated conversion and release process at
31 mM and completely blocked it at 125 mM. In keeping
with these profound effects of EST on ADAMTS4, the
abundance of MT4-MMP in the tissue (very little was found
in the medium) was markedly (more than 10-fold) enhanced
by IL-1 treatment and this effect was blocked by EST in
a dose-dependent manner over the concentration range
tested.
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Fig. 4. Western analysis of MT4-MMP in cartilage tissue and
conditioned medium. Cartilage was analyzed immediately after
harvest (Day 0) or incubated for 6 days in serum-free medium with
no treatment, 10 ng/ml IL-1, or IL-1 plus 1.35 mM ManN. IL-1
treatment resulted in a strong increase in MT4-MMP abundance
that was blocked by addition of ManN.REALTIME PCR ANALYSIS
To examine the possibility that the ManN blockade of IL-1
mediated aggrecanase activity in bovine cartilage explants
could be due to transcriptional inhibition we carried out
realtime PCR of ADAMTS4 and ADAMTS5 in this system.
The data (Fig. 6) shows that for both aggrecanases there
was a marked (w3-fold for ADAMTS4 and w10-fold for
ADAMTS5) increase in transcription 1 day after addition of
10 ng/ml IL-1 (P! 0.001 for both). There was no signiﬁcant
effect of ManN treatment alone, but ManN signiﬁcantly
inhibited the IL-1-induced increase in ADAMTS4
(PZ 0.047) and showed the same trend for ADAMTS5
(PZ 0.052).
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Fig. 5. EST inhibits IL-1-induced changes in ADAMTS4 and MT4-
MMP proteins. Cartilage tissue was treated for 6 days with 10 ng/ml
IL-1 and EST over a range of doses up to 500 mM. (A) The GAG
released from the tissue to the conditioned medium showed dose-
dependent inhibition of IL-1-induced GAG loss by EST (bars
indicate meanG S.E.M. for six replicates per group). Linear re-
gression analysis of rank-transformed EST dose vs GAG loss
showed a signiﬁcant trend (PZ 0.02 for NZ 4 doses). (B) Western
analysis for ADAMTS4 was performed on cartilage tissue extracts
and conditioned medium by probing with JSCVMA. Treatment with
IL-1 caused a prominent increase in medium abundance of p53 that
was blocked by addition of 125 mM EST. (C) Western analysis for
MT4-MMP in cartilage tissue and conditioned medium showed that
IL-1 treatment resulted in a strong increase in MT4-MMP
abundance, and this increase was blocked by addition of 125 mM
EST.
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IMPLICATIONS FOR ADAMTS4 PROCESSING
AND THE MECHANISM OF AGGRECANOLYSIS
The data provided both conﬁrm and extend current
models for the synthesis, processing and mode of action
of ADAMTS4 in aggrecan degradation. The importance of
the present work is that it provides evidence that the model
established in recombinant cell expression systems2,14,18 is
supportable when examined in live cartilage tissue in
explant culture.
The central features of this model include a secreted
furin-cleaved p68 protein2,13 which cannot cleave the IGD
of aggrecan but which has high activity toward the CS-
attachment region14,18. This p68 form can be presented on
the cell surface in association with MT4-MMP18 where it is
C-terminally cleaved by MT4-MMP to generate the p53
form, which can be found in association with syndecan-118,
and which readily cleaves at the IGD site of aggrecan to
destroy the biomechanical properties of the tissue29. The
MT4-MMP-mediated cleavage sites are the same as those
shown to occur during autoproteolysis of ADAMTS415,18.
In the present work we have shown that in a cartilage
explant, the IL-1-promoted and aggrecanase-mediated
sequential cleavage of the C-terminal and IGD of aggrecan
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Fig. 6. Realtime PCR analysis of ADAMTS4 and ADAMTS5.
Cartilage disks were incubated with no additives (control), 10 ng/ml
IL-1 (IL-1), 1.35 mM ManN, or the combination (IL-1CManN).
After 1 day of culture, mRNA was extracted and realtime PCR was
performed. Expression levels for (A) ADAMTS4 and (B) ADAMTS5
are shown relative to untreated control disks for three experiments
as individual data points (circles) and mean (bars). The effect of
ManN, IL-1, and the interaction between ManN and IL-1 was tested
for signiﬁcance by linear regression.[Fig. 1(A, B)] is not accompanied by a marked change in the
amount of ADAMTS4 protein but, in agreement with the
studies of Pratta et al.7, it appears to be due to activation of
an existing pool of enzyme [Figs. 3 and 5(B)]. The changes
induced by IL-1 were in the p68 form and the p53 form
(Fig. 3), both of which were found in the medium
compartment after 6 days. In time-course experiments
(not shown) the p68 form was found to be abundant at day 2
whereas the p53 form was only apparent after 6 days.
Given that the p68 form is conﬁned to C-terminal cleavage
of aggrecan14, the kinetics of appearance of the p68 and
p53 seen here are consistent with the ﬁnding that
C-terminal cleavage occurred early in the process
[Fig. 1(B)] and this was followed after about 4 days by
IGD cleavage [Fig. 1(A)]. These data, on detergent extracts
of cartilage tissue, show some differences from previous
observations of increased abundance of guanidine-extract-
able ADAMTS4 at 46 kDa14 or at w60 and 30 kDa9, which
may be explained by variable recovery of ADAMTS4 forms
depending on the extractant.
Of particular interest is the ﬁnding that both the p68 form
and the p53 form are released into the culture medium,
suggesting that their proposed cell surface associations
with MT4-MMP and syndecan-1, respectively18, are satu-
rable and/or reversible. Regarding the association of p68
with MT4-MMP, it is clear that MT4-MMP also increases in
abundance in the presence of IL-1 (Fig. 4) and that
a proportion of this newly synthesized GPI-anchored protein
is released from the cell and matrix under IL-1 stimulation.
While the p68eMT4-MMP complex can be released intact
from human chondrosarcoma cells by treatment with
phosphatidylinositol-speciﬁc phospholipase C18, it is un-
known whether the two proteins remain associated after
MT4-MMP release from the cell surface in the present
system. Interestingly, Itoh et al.17 have observed in COS
cells that the release of MT4-MMP from the cell surface is
partially inhibited by a metalloproteinase inhibitor, suggest-
ing that a member of the ADAM family of sheddases38
might also be involved in the aggrecanase cascade.
Alternatively, membrane vesiculation during IL-1 treat-
ment39 might provide an explanation for the release of the
MT4-MMP.
While the p68 form is found in both the tissue and the
medium, it appears that the p53 form is only abundant in the
medium, suggesting that all of the newly formed p53
dissociates from the cell surface syndecan-1 at some time
in the process. Again, while the association of p53 with the
GAG chains of syndecan-1 in chondrosarcoma cell culture
is stable to bi-directional immunoprecipitation protocols18, it
is not known whether the p53 in the cartilage explant is
released into the medium in association with syndecan-1
and/or aggrecan products. Elucidation of the binding
partners for the p68 and p53 forms in cartilage explants,
along with immunohistochemical characterization of the
spatial and temporal aspects of proteinase location and
substrate cleavage, will be required to fully understand this
complex pathway.
INHIBITION OF THE AGGRECANOLYSIS PATHWAY
The data reported also provide novel insight into the
mechanism by which inhibitors of the aggrecanase pathway
may operate. The ﬁndings that MMP inhibitors (such as
TIMP-1, peptide hydroxamates, etc.) can partially block
aggrecanolysis in tissue explants suggested early that
either MMP inhibitors can directly inhibit the ADAMTS4
275Osteoarthritis and Cartilage Vol. 13, No. 4catalytic domain, or alternatively that an MMP might be
involved in activation of aggrecanase30,40e42.
In support of this, in the present study we have shown
that EST, an inhibitor of MMP-1, 3, and 13 gene
transcription21,23 is also an inhibitor of aggrecanolysis
[Fig. 5(A)], p53 ADAMTS4 formation [Fig. 5(B)] and MT4-
MMP protein accumulation [Fig. 5(C)]. Since the IC50 is
about 50 mM for each of these three effects, it seems likely
that the EST effect operates primarily by blocking induction
of MT4-MMP synthesis by IL-1, which results in a lack of
conversion of p68 to p53, and a consequent loss of
destructive aggrecanolysis. The concentrations of EST
required to block cartilage resorption were not due to
cytotoxic effects. It has previously been reported that EST
concentrations of up to 500 mM had no effect on chon-
drocyte viability by measurement of LDH (lactate dehydro-
genase) release21. In addition, we have shown in
preliminary experiments that 500 mM EST does not affect
expression of TIMP-1 and GAPDH mRNAs as measured by
realtime PCR, indicating that transcription had not been
universally altered, and suggesting that the inhibition by
EST was not based on cytotoxic activity.
The other inhibitor studied here was ManN, which we
have suggested16,18 exerts its effect by inhibition of the GPI
anchor formation required for membrane insertion of MT4-
MMP. The present data are consistent with this idea since
1.35 mM ManN markedly (w80%) inhibited the IL-1-
induced production of MT4-MMP (Fig. 4) in the cartilage.
This predictably blocked the IL-1-induced accumulation of
p68 and p53 ADAMTS4 in the medium (Fig. 3). Interest-
ingly, in the presence of ManN there is a complete blockade
of IGD cleavage by p53; however, some C-terminal
cleavage to G1-TAGELE is observed (data not shown).
This is consistent with the idea that the pre-existing p68
would likely be active in the presence of ManN, since it
would not require further GPI anchor formation.
Finally, we show here (Fig. 6) that IL-1 treatment of
bovine chondrocytes in cartilage explants results in major
upregulation of mRNA for both ADAMTS4 (3-fold) and
ADAMTS5 (10-fold). This marked increase in transcriptional
activity for these proteinases was not accompanied by
major changes in the abundance of these proteins (data not
shown for ADAMTS5). This is consistent with the general
view that control of aggrecanolysis in cartilage by
inﬂammatory mediators such as IL-1, is initiated by
proteinase processing on the cell surface and release of
active enzyme into the matrix. Presumably prolonged
exposure to such mediators in joint diseases, with an
attendant upregulation of transcription, generates a contin-
uous supply of newly synthesized enzyme, which will
maintain the activity of this degradative cascade.
The upregulation of ADAMTS5 mRNA observed here is
not necessarily indicative of an increase in ADAMTS5
activity, but emphasizes that while the data presented here
has focused on activation of ADAMTS4, other family
members may also play a role in aggrecanolysis. In
particular, the recent ﬁndings in mice that the IL-1-induced
aggrecanase pathway to G1-NITEGE formation is appar-
ently not blocked by gene deletion of ADAMTS143 or
ADAMTS444 suggest that further analysis of the expression
and activation of the individual aggrecanases
(ADAMTS1,4,5,8,9,15) will be needed to fully deﬁne the
role of MT4-MMP in the aggrecanolysis associated with
human osteoarthritis.
As a general comment, it is important to note that the
effectiveness of ManN in this process should not be
interpreted as suggesting the use of ManN in place ofglucosamine for therapy of human osteoarthritis. ManN,
unlike glucosamine, is a potent inhibitor of GPI-anchor
synthesis16, which is necessary for the anchoring and
function of multiple essential cell-surface proteins45,46.
ManN ingestion is therefore likely to have profound side
effects, which should preclude its use as a therapeutic.
Our evidence for the involvement of MT4-MMP in
aggrecanolysis in cartilage tissue culture also has implica-
tions for the interpretation of MMP inhibitor studies. For ex-
ample, some ‘‘broad-spectrum’’ MMP inhibitors reportedly
do not inhibit aggrecanase activity40. However, it is not clear
whether all broad-spectrum MMP inhibitors are active
against MT-MMPs, which were not characterized until
1999, and may have some unique features in the structure
of their catalytic domains47. It is therefore intriguing that
CGS20723A, a broad-spectrum MMP inhibitor that potently
inhibits the catalytic domain of MT4-MMP in solution48,
does not appear to inhibit overall IL-1-induced GAG loss in
tissue culture, but has been reported to protect against loss
of pericellular GAG staining49. This could be explained if
loss of pericellular GAG staining is due to p53 generated by
MT4-MMP, whereas more generalized aggrecanolysis in
the intercellular matrix is due to p68 and therefore conﬁned
to the C-terminal of aggrecan. Thus, the requirement for
MT4-MMP for aggrecanolysis suggested by the present
data may not extend to all experimental situations, and the
development of speciﬁc small-molecule MT-MMP inhibitors
may in future be useful for testing these hypotheses.
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